REGULATORY

Drug Pricing Organization to Price JCR’s Cell Therapy Temcell

October 1, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) agreed on September 30 that the reimbursement price of JCR Pharmaceuticals’ recently approved cell-based therapy will be set by the Drug Pricing Organization as the product has characteristics close to those of pharmaceuticals.…

To read the full story

Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015

REGULATORY

Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…